Výsledky vyhledávání

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study

Autor: Parameswaran Venugopal, Elias Jabbour, Stephen A. Strickland, Karen Seiter, Martha Arellano, Gary J. Schiller, Steven Coutre, David F. Claxton, Wendy Stock, Selina M. Luger, Lori J. Maness, Meir Wetzler, Stuart L. Goldberg, Hagop M. Kantarjian, William Plunkett, Stefan Faderl, Judy Chiao, Guillermo Garcia-Manero

Publikováno v: The Lancet Oncology. 13:1096-1104

Summary Background Available treatments for acute myeloid leukaemia (AML) have limited durable activity and unsatisfactory safety profiles in most elderly patients. We assessed the efficacy and toxicity of sapacitabine, a novel oral cytosine nucleosi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec78275e80d98926f3bb2ed8889031f4
https://doi.org/10.1016/s1470-2045(12)70436-9

Zobrazit plný text záznamu

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Autor: Parul Hazarika, Chunlei Zhang, Cecilia Kelly, Stanley R. Frankel, Justin L. Ricker, John F. Reilly, Judy Chiao, Rakhshandra Talpur, Xiao Ni, Madeleine Duvic, Victoria M. Richon

Publikováno v: Blood. 109:31-39

The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL). Group 1 received vorinostat 400 mg daily, group 2 received vo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee11ad98aeec58dffc008ec32449541c
https://doi.org/10.1182/blood-2006-06-025999

Zobrazit plný text záznamu

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

Autor: L. Sun, Eileen Reilly, Syed Rizvi, Carol Oerth, Laura McBride, Constantine S. Mitsiades, Judy Chiao, Kathleen Colson, Ivy Fearen, Justin L. Ricker, Paul G. Richardson, Kenneth C. Anderson, Barbara Atkins, David Siegel

Publikováno v: Leukemialymphoma. 49(3)

A Phase I trial (NCT00109109) of oral vorinostat 200, 250 or 300 mg twice daily for 5 days/week/4-week cycle or 200, 300, or 400 mg twice daily for 14 days/3-week cycle until progressive disease or intolerable toxicity was conducted. Patients with me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6901cbf013b13150aee6fe439b82fbee
https://pubmed.ncbi.nlm.nih.gov/18297514

Zobrazit plný text záznamu

Plný text ve formátu HTML

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

Autor: Cong Chen, Charles Lu, George R. Blumenschein, Ashok Kumar, Justin L. Ricker, Merrill S. Kies, Judy Chiao, Stanley R. Frankel, Vassiliki A. Papadimitrakopoulou

Publikováno v: Investigational new drugs. 26(1)

This phase II trial was initiated to assess the efficacy and safety of oral vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Eligible patients must have recurrent and/or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a94a39b026064792df0d01cb52c91158
https://pubmed.ncbi.nlm.nih.gov/17960324

Zobrazit plný text záznamu

A Randomized Phase II Study Of Sapacitabine In MDS Refractory To Hypomethylating Agents

Autor: Hagop M. Kantarjian, Karen Seiter, Jessica K. Altman, Martha Arellano, Selina M. Luger, Stuart L. Goldberg, Meir Wetzler, Guillermo Garcia-Manero, Judy Chiao

Publikováno v: Blood. 122:2752-2752

Background Sapacitabine is an orally administered nucleoside analogue which causes single-strand DNA breaks and induces G2 cell cycle arrest. A multi-center, randomized phase 2 study was conducted to evaluate 3 dose regimens in older patients with MD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e62bf2d89a0b2ca2fddf3a8f3385068b
https://doi.org/10.1182/blood.v122.21.2752.2752

Zobrazit plný text záznamu

Phase 1/ 2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML

Autor: Judy Chiao, Gautam Borthakur, Patricia Ann Boone, Stefan Faderl, Guillermo Garcia-Manero, Tapan M. Kadia, Parameswaran Venugopal, Elias Jabbour, Farhad Ravandi, Hagop M. Kantarjian, Jorge E. Cortes, Meir Wetzler, William G. Wierda

Publikováno v: Blood. 118:3630-3630

Abstract 3630 Background: Sapacitabine is a novel nucleoside analogue with a unique ability to induce single-strand DNA breaks after incorporation into DNA, leading to production of double strand DNA breaks and/or G2 cell cycle arrest. It is orally a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::75d79c6bb4c78aa2586f46d5e021c858
https://doi.org/10.1182/blood.v118.21.3630.3630

Zobrazit plný text záznamu

A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, In Older Patients with MDS Refractory to Hypomethylating Agents

Autor: Guillermo Garcia-Manero, Jessica K. Altman, Stuart L. Goldberg, Judy Chiao, James M. Foran, Stephen A. Strickland, Lori J. Maness, David F. Claxton, Hagop M. Kantarjian, Meir Wetzler, P. Venugopal, Selina M. Luger

Publikováno v: Blood. 116:1857-1857

Abstract 1857 This study is registered with ClinicalTrials.gov, number NCT00590187. Background: Sapacitabine is an orally administered nucleoside analogue with a unique ability to cause irreparable single-strand DNA breaks and induce G2 cell cycle ar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::298c6fc24fc590eb8b9bf9b88d2d39fa
https://doi.org/10.1182/blood.v116.21.1857.1857

Zobrazit plný text záznamu

A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Elderly Patients with AML Previously Untreated or in First Relapse

Autor: Lori J. Maness, Steven Coutre, Wendy Stock, Selina M. Luger, Gautam Borthakur, Parameswaran Venugopal, Hagop M. Kantarjian, Meir Wetzler, Guillermo Garcia-Manero, Judy Chiao

Publikováno v: Blood. 114:1061-1061

Abstract 1061 Poster Board I-83 Introduction: Sapacitabine is a novel nucleoside analogue with a unique ability to cause irreparable single-strand DNA breaks and induce G2 cell cycle arrest. It is orally administered and has demonstrated promising an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::89a86985bf2fc192a21ab200610029b7
https://doi.org/10.1182/blood.v114.22.1061.1061

Zobrazit plný text záznamu

Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma

Autor: Ivy Fearen, Kenneth C. Anderson, Paul G. Richardson, David S. Siegel, Syed Rizvi, L. Sun, Barbara Atkins, Laura McBride, Carol Oerth, Eileen Reilly, Constantine S. Mitsiades, Judy Chiao, Kathleen Colson, Justin L. Ricker

Publikováno v: Blood. 110:1179-1179

Background: The histone deacetylase inhibitor vorinostat was approved by the United States FDA in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent dise

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b37bbc24ef1a30ee8e1813f8f842a886
https://doi.org/10.1182/blood.v110.11.1179.1179

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání